Trials / Completed
CompletedNCT05324293
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 Over a 24-Week Treatment Period
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HMI-115 | Once Every 2 weeks, subcutaneously injection |
Timeline
- Start date
- 2022-05-11
- Primary completion
- 2023-09-11
- Completion
- 2023-09-11
- First posted
- 2022-04-12
- Last updated
- 2024-09-19
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05324293. Inclusion in this directory is not an endorsement.